The tyrosine kinase 2 (TYK2) inhibitor deucravacitinib, approved for treating psoriasis,50 is currently being trialled in a phase III RCT for SLE after meeting its primary and key secondary endpoints in a phase II trial.51 The gene discussed is TYK2; the disease is systemic lupus erythematosus.